Table 1.
Demographics and clinical information, mean (standard deviation)
| HC (N = 22) | AD (N = 28) | LBD (N = 39) | Between-group differences | |
|---|---|---|---|---|
| Male:female | 15:7 | 22:6 | 34:5 | χ2 = 3.18, p = 0.20a |
| Age | 75.9 (5.4) | 76.6 (8.1) | 75.5 (5.5) | F2,86 = 0.22, p = 0.80b |
| AChEI | na | 26 | 35 | χ2 = 0.19, p = 0.66c |
| PD meds | na | 0 | 28 | χ2 = 34.54, p < 0.001c |
| Duration | na | 3.9 (2.1) | 3.0 (1.9) | U = 395, p = 0.05d |
| MMSE | 29.2 (0.9) | 21.8 (3.1) | 23.5 (3.7) | t65 = 1.94, p = 0.06e |
| CAMCOG | 96.7 (3.7) | 71.0 (11.5) | 76.2 (12.5) | t65 = 1.73, p = 0.09e |
| UPDRS | 1.1 (1.4) | 2.1 (2.0) | 19.2 (8.4) | t65 = 10.47, p < 0.001e |
| CAF total | na | 0.7 (1.7)f | 5.0 (4.7) | t64 = 4.46, p < 0.001e |
| Mayo total | na | 8.8 (4.0)f | 13.2 (5.9) | t64 = 3.39, p = 0.001e |
| Mayo cogn | na | 1.8 (1.8)f | 2.7 (1.9) | t64 = 1.96, p = 0.05e |
| NPI total | na | 6.9 (6.4)f | 13.3 (10.4) | t64 = 2.89, p = 0.005e |
| NPI hall | na | 0.04 (0.2)f | 1.7 (2.1) | t64 = 4.14, p < 0.001e |
AChEI number of patients taking acetylcholinesterase inhibitors, AD Alzheimer’s disease, CAF total Clinical Assessment of Fluctuations total score, CAMCOG Cambridge Cognitive Examination, Duration duration of cognitive symptoms in years, HC healthy controls, LBD Lewy body dementia, Mayo cogn Mayo Fluctuations Cognitive Subscale, Mayo total, Mayo Fluctuations Scale, Mayo arousal Mayo Fluctuations Arousal Subscale, MMSE Mini Mental State Examination, na not applicable, PD meds number of patients taking dopaminergic medication, UPDRS Unified Parkinson’s Disease Rating Scale III, NPI Neuropsychiatric Inventory, NPI hall NPI Hallucination Subscore
aChi-square test HC, AD, DLB
bOne-way ANOVA HC, AD, DLB
cChi-square test AD, DLB
dMann–Whitney U test AD, DLB
eStudent’s t test AD, DLB
fN = 27